Timothy Cardozo

Summary

Affiliation: New York University School of Medicine
Country: USA

Publications

  1. pmc Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes
    James Swetnam
    Department of Pharmacology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e15994. 2010
  2. pmc Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects
    Evgeny Shmelkov
    Department of Pharmacology, New York University School of Medicine NYUSoM, New York, New York, United States of America
    PLoS ONE 6:e27279. 2011
  3. pmc Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies
    Timothy Cardozo
    New York University School of Medicine, Departments of Pharmacology, Pathology and Environmental Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 25:441-50. 2009
  4. pmc Quantitative assessment of masking of neutralization epitopes in HIV-1
    Alpna Agarwal
    Department of Pharmacology, New York University School of Medicine, 550 First Avenue MSB 497, New York, NY 10016, USA
    Vaccine 29:6736-41. 2011
  5. pmc Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop
    David Almond
    Department of Pharmacology, New York University School of Medicine NYUSoM, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 26:717-23. 2010
  6. pmc Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA
    Susan Zolla-Pazner
    Veterans Affairs Medical Center, New York, NY, USA
    J Virol 85:9887-98. 2011
  7. pmc Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 6:e27780. 2011
  8. pmc Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial
    Susan Zolla-Pazner
    Research Service, Veterans Affairs Medical Center, New York, New York, United States of America
    PLoS ONE 8:e53629. 2013
  9. ncbi request reprint Structural basis for coreceptor selectivity by the HIV type 1 V3 loop
    Timothy Cardozo
    Department of Pharmacology and New York University School of Medicine, New York, NY 10016, USA
    AIDS Res Hum Retroviruses 23:415-26. 2007
  10. doi request reprint Conserved structural elements in the V3 crown of HIV-1 gp120
    Xunqing Jiang
    Department of Biochemistry, New York University School of Medicine, New York, New York, USA
    Nat Struct Mol Biol 17:955-61. 2010

Collaborators

Detail Information

Publications17

  1. pmc Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopes
    James Swetnam
    Department of Pharmacology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 5:e15994. 2010
    ..Our results suggest one way to quantify and compare the magnitude of the conservation...
  2. pmc Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjects
    Evgeny Shmelkov
    Department of Pharmacology, New York University School of Medicine NYUSoM, New York, New York, United States of America
    PLoS ONE 6:e27279. 2011
    ....
  3. pmc Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies
    Timothy Cardozo
    New York University School of Medicine, Departments of Pharmacology, Pathology and Environmental Medicine, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 25:441-50. 2009
    ..More importantly, these calculations demonstrate that globally relevant, structurally conserved epitopes are present in the sequence variable V3 loop...
  4. pmc Quantitative assessment of masking of neutralization epitopes in HIV-1
    Alpna Agarwal
    Department of Pharmacology, New York University School of Medicine, 550 First Avenue MSB 497, New York, NY 10016, USA
    Vaccine 29:6736-41. 2011
    ..These results have important implications for rational design of vaccines designed to induce neutralizing Abs by revealing epitopes that are minimally masked and maximally reactive with neutralizing Abs...
  5. pmc Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop
    David Almond
    Department of Pharmacology, New York University School of Medicine NYUSoM, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 26:717-23. 2010
    ..From a structural point of view, there appears to be less diversity in this region of the HIV-1 "principle neutralizing domain" than previously appreciated...
  6. pmc Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA
    Susan Zolla-Pazner
    Veterans Affairs Medical Center, New York, NY, USA
    J Virol 85:9887-98. 2011
    ....
  7. pmc Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure
    Miroslaw K Gorny
    Department of Pathology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 6:e27780. 2011
    ..This will be useful information for designing vaccine immunogen inducing cross-neutralizing Abs...
  8. pmc Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial
    Susan Zolla-Pazner
    Research Service, Veterans Affairs Medical Center, New York, New York, United States of America
    PLoS ONE 8:e53629. 2013
    ....
  9. ncbi request reprint Structural basis for coreceptor selectivity by the HIV type 1 V3 loop
    Timothy Cardozo
    Department of Pharmacology and New York University School of Medicine, New York, NY 10016, USA
    AIDS Res Hum Retroviruses 23:415-26. 2007
    ..The results have additional implications for the design of HIV therapeutics, vaccines, and strategies for monitoring disease progression...
  10. doi request reprint Conserved structural elements in the V3 crown of HIV-1 gp120
    Xunqing Jiang
    Department of Biochemistry, New York University School of Medicine, New York, New York, USA
    Nat Struct Mol Biol 17:955-61. 2010
    ..As these regions are targeted by cross-clade neutralizing human antibodies, they provide a blueprint for the design of vaccine immunogens that could elicit broadly cross-reactive protective antibodies...
  11. pmc Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies
    David Almond
    Department of Pharmacology, New York University School of Medicine NYSoM, New York, NY 10016, USA
    Adv Virol 2012:803535. 2012
    ..As antibodies to a variable loop were recently identified as an inverse correlate of risk for HIV infection, the structure-function relationships discussed in this study may have relevance to HIV vaccine research...
  12. pmc Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design
    Susan Zolla-Pazner
    Veterans Affairs New York Harbor Healthcare System, Manhattan Campus, New York 10010, USA
    Nat Rev Immunol 10:527-35. 2010
    ..Recombinant immunogens that include these features may provide the means to address the antigenic diversity of HIV-1 and induce protective antibodies that can prevent infection with HIV-1...
  13. pmc HIV's Nef interacts with β-catenin of the Wnt signaling pathway in HEK293 cells
    Keren Weiser
    Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 8:e77865. 2013
    ..The interaction between Nef and β-catenin was confirmed in vitro and in a co-immunoprecipitation from HEK293 cells. Moreover, the introduction of Nef into HEK293 cells specifically inhibited a Wnt pathway reporter. ..
  14. pmc Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodies
    Evgeny Shmelkov
    Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, United States of America
    PLoS ONE 9:e89987. 2014
    ..The defined epitopes can also be used for the purpose of epitope-specific analyses of breakthrough sequences recorded in vaccine clinical trials. Thus, our study is a prototype for a valuable tool for rational HIV-1 vaccine design. ..
  15. pmc Distinct sequence patterns characterize the V3 region of HIV type 1 gp120 from subtypes A and C
    Klara Felsovalyi
    Department of Pharmacology, New York University School of Medicine and the New York Veterans Affairs Medical Center, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 22:703-8. 2006
    ..This lowest limit was 10(16). Although theoretically a p-value cannot be equal to 0.0, the p-value for the comparisons in question can be intuitively considered to be extremely small, or approximately 0.0.)...
  16. pmc Structural determinants of PERK inhibitor potency and selectivity
    Hong Wang
    Department of Pharmacology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA
    Chem Biol Drug Des 76:480-95. 2010
    ..Interestingly, the activation loop contact is required for PERK selectivity to emerge. Understanding these structure-activity relationships may accelerate rational PERK inhibitor design...
  17. ncbi request reprint Modeling the interaction between aldolase and the thrombospondin-related anonymous protein, a key connection of the malaria parasite invasion machinery
    Carlos A Buscaglia
    Michael Heidelberg Division of Pathology of Infectious Diseases, Department of Pathology, New York University School of Medicine, New York, USA
    Proteins 66:528-37. 2007
    ..Enzymatic and TRAP-binding assays using mutant PfAldo molecules strongly support the overall structural model. These results might provide the initial framework for the identification of novel antiparasitic compounds...